Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for NERV.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2013. Start Trial.
Date Value
June 30, 2026 -213.30M
March 31, 2026 -254.01M
December 31, 2025 -140.75M
September 30, 2025 -34.58M
June 30, 2025 -32.11M
March 31, 2025 -29.15M
December 31, 2024 -25.69M
September 30, 2024 -21.67M
June 30, 2024 -44.49M
March 31, 2024 -36.59M
December 31, 2023 -28.46M
September 30, 2023 -20.05M
June 30, 2023 -12.51M
March 31, 2023 -26.62M
December 31, 2022 -20.02M
September 30, 2022 -14.25M
June 30, 2022 -8.382M
March 31, 2022 -0.7361M
December 31, 2021 7.976M
September 30, 2021 28.08M
June 30, 2021 36.17M
March 31, 2021 45.37M
December 31, 2020 52.66M
September 30, 2020 58.02M
June 30, 2020 56.94M
Date Value
March 31, 2020 18.62M
December 31, 2019 27.78M
September 30, 2019 55.53M
June 30, 2019 67.27M
March 31, 2019 77.42M
December 31, 2018 90.26M
September 30, 2018 101.39M
June 30, 2018 110.66M
March 31, 2018 121.29M
December 31, 2017 131.60M
September 30, 2017 130.18M
June 30, 2017 98.03M
March 31, 2017 106.29M
December 31, 2016 105.98M
September 30, 2016 113.14M
June 30, 2016 120.60M
March 31, 2016 66.65M
December 31, 2015 55.32M
September 30, 2015 63.07M
June 30, 2015 68.38M
March 31, 2015 74.44M
December 31, 2014 51.50M
September 30, 2014 56.72M
June 30, 2014 29.23M
March 31, 2014 34.09M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 1.307B
Alnylam Pharmaceuticals, Inc. 1.354B
Anika Therapeutics, Inc. 137.28M
Savara, Inc. 143.66M
Vericel Corp. 370.04M

Shareholders Equity (Quarterly) Related Metrics